| scholarly article | Q13442814 |
| P2093 | author name string | Ran Friedman | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Natural selection's challenge to the cancer stem cell hypothesis | Q81294710 | ||
| Targeting apoptosis pathways in cancer therapy | Q81742188 | ||
| Evaluating evolutionary models of stress-induced mutagenesis in bacteria | Q86095467 | ||
| Keeping pace with cancer | Q86673238 | ||
| The effects of X-rays on the proliferation dynamics of cells in the imaginal wing disc ofDrosophila melanogaster | Q89557974 | ||
| Fitness and its role in evolutionary genetics | Q22122004 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
| The influence of subclonal resistance mutations on targeted cancer therapy | Q26781693 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Discovery of Potent and Selective Covalent Inhibitors of JNK | Q27676927 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell | Q27861001 | ||
| A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 | ||
| Aspirin and clopidogrel resistance: an emerging clinical entity | Q28194021 | ||
| Normal stem cells and cancer stem cells: the niche matters | Q28237647 | ||
| The clonal evolution of tumor cell populations | Q28271546 | ||
| Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia | Q28478165 | ||
| Drug resistance missense mutations in cancer are subject to evolutionary constraints | Q28537830 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information | Q29547192 | ||
| Clonal evolution in cancer | Q29547696 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| Tumour heterogeneity and cancer cell plasticity | Q29617990 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| S100A4 and its role in metastasis – computational integration of data on biological networks | Q30977149 | ||
| Apoptotic cells activate the "phoenix rising" pathway to promote wound healing and tissue regeneration | Q34001599 | ||
| Oncogenic resistance to growth-limiting conditions | Q34126792 | ||
| Evolution of the cancer stem cell model | Q34408981 | ||
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer. | Q34447778 | ||
| The paradox of response and survival in cancer therapeutics | Q34449433 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| Rituximab resistance | Q35041270 | ||
| Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants | Q35221149 | ||
| Apoptosis in cancer: from pathogenesis to treatment | Q35397889 | ||
| Antiangiogenic therapy and tumor progression | Q35641618 | ||
| Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance | Q35735937 | ||
| Targeted cancer therapy | Q35953128 | ||
| Cancer research meets evolutionary biology. | Q35960758 | ||
| Carcinogenesis, cancer therapy and chemoprevention | Q36092823 | ||
| The role of apoptosis-induced proliferation for regeneration and cancer | Q36119477 | ||
| Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance | Q36315504 | ||
| Target for cancer therapy: proliferating cells or stem cells | Q36343524 | ||
| Drugs that target pathogen public goods are robust against evolved drug resistance | Q36382702 | ||
| BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships | Q36542821 | ||
| Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors | Q36595762 | ||
| Targeted therapy for cancer stem cells: the patched pathway and ABC transporters | Q36745386 | ||
| Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). | Q36822880 | ||
| Cancer stem cells: the theory and perspectives in cancer therapy. | Q37147649 | ||
| Is tumor growth sustained by rare cancer stem cells or dominant clones? | Q37179962 | ||
| Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment | Q37604241 | ||
| The cancer stem cell: premises, promises and challenges | Q37851011 | ||
| BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet | Q37874391 | ||
| Cancer stem cells: current status and evolving complexities | Q38019174 | ||
| Pushing the limits of targeted therapy in chronic myeloid leukaemia. | Q38028778 | ||
| Cellular heterogeneity and molecular evolution in cancer | Q38054794 | ||
| The 2 Faces of JNK Signaling in Cancer. | Q38172163 | ||
| S100A4 and its role in metastasis – simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases | Q38865767 | ||
| Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. | Q38942785 | ||
| Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells | Q39253278 | ||
| Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression | Q39910362 | ||
| Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. | Q39975225 | ||
| STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562. | Q40001664 | ||
| Evolution of resistance during clonal expansion | Q40288205 | ||
| Population genetics of cancer cell clones: possible implications of cancer stem cells | Q41366407 | ||
| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia | Q41980844 | ||
| Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain | Q42811718 | ||
| Evolution of resistance to anti-cancer therapy during general dosing schedules | Q42909218 | ||
| New concepts for CML clonality | Q43105348 | ||
| Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. | Q44071998 | ||
| Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells | Q44192405 | ||
| Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia | Q44381170 | ||
| Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia | Q45006858 | ||
| Paul Ehrlich's magic bullet concept: 100 years of progress | Q48322740 | ||
| Defeating pathogen drug resistance: guidance from evolutionary theory. | Q51678714 | ||
| Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways. | Q52652438 | ||
| Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia | Q56996659 | ||
| Selection and adaptation during metastatic cancer progression | Q59081706 | ||
| Differentiation of malignant to benign cells | Q71761365 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug resistance | Q12147416 |
| P304 | page(s) | 11746-11755 | |
| P577 | publication date | 2016-02-17 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Drug resistance in cancer: molecular evolution and compensatory proliferation | |
| P478 | volume | 7 |
| Q55001065 | A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy. |
| Q89602042 | APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy |
| Q54114106 | Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6. |
| Q90103101 | Drosophila Model in Cancer: An Introduction |
| Q50044775 | Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. |
| Q92382614 | Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway |
| Q97905534 | Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters |
| Q64996441 | Limiting tumor seeding as a therapeutic approach for metastatic disease. |
| Q93056726 | Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA |
| Q37723172 | Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein |
| Q96834102 | Signature-based approaches for informed drug repurposing: targeting CNS disorders |
| Q64956787 | Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia. |
| Q61806252 | Systematic analysis of NLMP suggests nuclear localization of RTK/MET kinases resemble cancer cell clearance |
| Q90341470 | Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma |
| Q55378234 | The organic ester O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate dihydrochloride attenuates murine breast cancer growth and metastasis. |
| Q64101409 | Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy |
Search more.